Cancer, Lipids, and Metabolism

This study identifies FASN as a regulator of mTOR signaling and histone crotonylation during cardiomyocyte hypertrophy, linking lipid metabolism to epigenetic changes and cardiac disease.

FASN-driven lipogenesis sustains EGFR palmitoylation and PI3K-AKT-mTOR signaling, suppressing tumor MHC-I antigen presentation; blocking it curbs TNBC metastasis in mice via CD8 T cell recognition.

This study identifies ANO6 as a scaffold at ER-mitochondria contacts that facilitates lipid sequestration and ferroptosis evasion in chemoresistant breast cancer.

This paper reports the discovery of SBP-5917, a reversible FASN-TE inhibitor with submicromolar potency and cellular target engagement.

This study identifies KRAS-driven metabolic reprogramming through MFSD2A-mediated lysophosphatidylcholine scavenging as a driver of PDAC progression and shows that targeting this pathway with edelfosine has anti-cancer effects.

This paper identifies VCB1, a novel ACLY inhibitor, which overcomes TKI resistance in lymphoma by disrupting lipid and nucleotide metabolism, ISR, and redox homeostasis.

This paper identifies treatment-resilient lipid remodeling in TMZ-resistant glioblastoma cells, showing that resistance is linked to coordinated changes in multiple lipid families rather than single species.

This study identifies ALDH1B1's role in mitochondrial GBB and GABA biosynthesis, enhancing fatty acid oxidation in CRC and linking it to tumor progression.

This study shows that dietary saturated fatty acid chain length affects B-cell lymphoma metabolism and progression, with medium-chain fatty acids promoting tumor growth and long-chain fatty acids restricting it.

This study shows that inhibiting de novo lipogenesis and supplementing with PUFAs suppresses prostate cancer progression by inducing oxidative stress and cell death.

This study shows that inhibiting SREBP1 with Nelfinavir improves chemotherapy response in obesity-associated ovarian cancer by reprogramming the immune microenvironment.

This study investigates the effect of statins on ovarian cancer survival, finding that atorvastatin improves survival and enhances immune activation in preclinical models.

This study shows that combining ACLY and OGDH inhibitors VPA and BA synergistically inhibits HCC cell lines with minimal toxicity to normal liver cells.

This paper identifies TMEM132A as a pan-cancer target that stabilizes EGFR and drives lipid synthesis, and develops a nanobody to inhibit this interaction, showing antitumor activity in resistant models.

This study identifies cholesterol dependency as a therapeutic target in glioblastoma, showing that combined treatment with clemastine and bexarotene induces metabolic collapse and enhances antitumor immunity.

This study identifies metabolic partnerships between medulloblastoma and macrophages that drive leptomeningeal metastases and suggests targeting the CXCL12-SCARB1-cholesterol axis as a therapeutic strategy.

This study identifies BMAds as drivers of prostate cancer bone metastasis through lipid-mediated induction of ANGPTL4, showing its clinical relevance as a therapeutic target.

This study shows that PCIF1 loss enhances cholesterol biosynthesis, promoting antitumour immunity by increasing CD8+ T cell infiltration and improving response to immune checkpoint blockade.

This paper presents cryo-EM structures of human FATP2, revealing its fatty acid uptake mechanism and drug inhibition strategies.

This study shows acidosis enhances fatty acid uptake in endothelial cells, leading to lipid droplet formation, ER stress, and reduced nitric oxide, contributing to endothelial dysfunction.

This study identifies CB5 (grassofermata) as a potential inhibitor of ACSVL3, showing reduced glioma cell growth and malignancy in vitro and in vivo.

This study identifies vincamine as a selective CPT1b inhibitor using a high-throughput assay, expanding the known isoform profile of chlorpromazine and demonstrating the feasibility of selective CPT1 isoform modulation.

This study identifies TROLL-8 as a regulator of fatty acid oxidation in breast cancer, showing its role in promoting tumorigenesis through CPT1A interaction.

This paper shows that inhibiting SCD1 with MF-438 enhances TMZ effectiveness in IDH1-mutant glioma mouse models by inducing lipotoxic stress and ferroptosis.

This study identifies lysosomal lipid metabolism as a driver of pancreatic cancer cell invasion through local energy production and membrane remodeling.

The paper identifies malonate as an endogenous intermediate supporting mitochondrial fatty acid synthesis and oxidative phosphorylation, showing ACC1-dependent synthesis from glucose.

This study examines how high-fat and high-iron diets affect liver tumorigenesis and transcriptomic changes in mice, finding shared and distinct molecular effects.

This study identifies a 10-gene mitochondrial fatty acid oxidation suppression signature common across breast cancer subtypes, validated in multiple cohorts and associated with survival.

This study shows that LEO1 loss in colorectal cancer promotes ER stress-adapted migration and cholesterol dependency, suggesting therapeutic targets for metastatic LEO1-low CRC.

This study shows that FASN inhibition restores radiosensitivity in chordoma by targeting adaptive fatty acid metabolism that protects against radiotherapy-induced damage.